Literature DB >> 23747132

Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma.

A Modesto1, P Blanchard, Y G Tao, M Rives, F Janot, E Serrano, A Benlyazid, J Guigay, F R Ferrand, J P Delord, J Bourhis, N Daly-Schveitzer.   

Abstract

PURPOSE/
OBJECTIVES: To analyze the clinical features, treatment modalities and outcome of patients treated for a localized esthesioneuroblastoma (ENB).
MATERIALS AND METHODS: Forty-three consecutive patients with biopsy proven ENB treated at two referral cancer centers between 1998 and 2010 were retrospectively reviewed.
RESULTS: Overall, 5 patients had stage A disease, 13 stage B, 16 stage C and 9 stage D according to the modified Kadish classification. Neo-adjuvant chemotherapy was performed in 23 patients leading to a 74 % response rate. Thirty-one patients were treated by surgery. Thirty-nine patients (90.6%) underwent radiation therapy. Twelve patients received bilateral cervical lymph node irradiation (LNI). After a median follow-up of 77 months, the 5-year overall and progression free survival were 65% and 57%. Twelve patients (28%) had a locoregional relapse leading to 10 ENB-related deaths. The major prognostic factor was the modified Kadish stage with a 3-year survival for stage A-B, C and D of 100%, 48% and 22% respectively (p < 0.0001). Two (9%) isolated cervical lymph node relapses occurred among staged B and C patients treated without elective LNI and none after elective or adjuvant LNI.
CONCLUSION: The high risk of locoregional failure in ENB justifies the use of multimodal therapy. Induction chemotherapy leads to a high response rate. Elective LNI might prevent regional failure in locally advanced disease.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Concurrent chemotherapy; Elective neck irradiation; Esthesioneuroblastoma; Intensity Modulated Radiation Therapy; Neo-adjuvant chemotherapy; Olfactory neuroblastoma

Mesh:

Year:  2013        PMID: 23747132     DOI: 10.1016/j.oraloncology.2013.04.013

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  10 in total

Review 1.  Olfactory Neuroblastoma.

Authors:  Ahmed S Abdelmeguid
Journal:  Curr Oncol Rep       Date:  2018-02-07       Impact factor: 5.075

2.  Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma.

Authors:  Rohan R Joshi; Qasim Husain; Benjamin R Roman; Jennifer Cracchiolo; Yao Yu; Jillian Tsai; Julie Kang; Sean McBride; Nancy Y Lee; Luc Morris; Ian Ganly; Viviane Tabar; Marc A Cohen
Journal:  J Surg Oncol       Date:  2018-11-22       Impact factor: 3.454

3.  Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database.

Authors:  Neeraja Konuthula; Alfred M Iloreta; Brett Miles; Ryan Rhome; Umut Ozbek; Eric M Genden; Marshall Posner; Krzysztof Misiukiewicz; Satish Govindaraj; Raj Shrivastava; Vishal Gupta; Richard L Bakst
Journal:  Head Neck       Date:  2017-08-17       Impact factor: 3.147

4.  Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience.

Authors:  Tongxin Liu; Quanquan Sun; Weifeng Qin; Xiaozhong Chen; Qiaoying Hu
Journal:  Cancer Manag Res       Date:  2020-09-10       Impact factor: 3.989

5.  Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.

Authors:  Takashi Mori; Rikiya Onimaru; Shunsuke Onodera; Kazuhiko Tsuchiya; Koichi Yasuda; Hiromitsu Hatakeyama; Hiroyuki Kobayashi; Shunsuke Terasaka; Akihiro Homma; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2015-04-15       Impact factor: 3.481

6.  Ectopic primary olfactory neuroblastoma of the nasopharynx: A case report and review of the literature.

Authors:  Nicholas J Caldwell; T Shawn Sato
Journal:  Radiol Case Rep       Date:  2019-06-06

7.  Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients.

Authors:  Meng Sun; Kai Wang; Yuan Qu; Jianghu Zhang; Shiping Zhang; Xuesong Chen; Jingbo Wang; Runye Wu; Ye Zhang; Junlin Yi; Jianping Xiao; Guozhen Xu; Xiaodong Huang; Jingwei Luo
Journal:  Radiat Oncol       Date:  2020-09-18       Impact factor: 3.481

8.  Olfactory Neuroblastoma: Surgical Treatment Experience of 42 Cases.

Authors:  Xiao Cai; Zhouying Peng; Hua Zhang; Ruohao Fan; Yan Fang; Zhihai Xie
Journal:  Front Surg       Date:  2022-02-01

9.  Dramatic response to targeted therapy in an aggressive olfactory neuroblastoma: illustrative case.

Authors:  Saksham Gupta; Wenya Linda Bi; Donald J Annino; Ian F Dunn
Journal:  J Neurosurg Case Lessons       Date:  2022-06-13

10.  Olfactory neuroblastoma treated with minimally invasive surgery and adjuvant radiotherapy: a case report and review of the literature.

Authors:  Domenico Cante; Cristina Piva; Piera Sciacero; Pierfrancesco Franco; Edoardo Petrucci; Valeria Casanova Borca; Fabrizio Marola; Libero Tubino; Giorgio Vellani; Maria Rosa La Porta
Journal:  BJR Case Rep       Date:  2018-01-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.